Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ANTENGENE Aktie

 >ANTENGENE Aktienkurs 
0.593 EUR    (TradegateBSX)
Ask: 0.625 EUR / 11147 Stück
Bid: 0.56 EUR / 12606 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
ANTENGENE Aktie über LYNX handeln
>ANTENGENE Performance
1 Woche: +17,3%
1 Monat: +84,6%
3 Monate: +39,1%
6 Monate: -18,3%
1 Jahr: +58,8%
laufendes Jahr: +44,9%
>ANTENGENE Aktie
Name:  ANTENGENE CORP. DL-,0001
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG039571008 / A2QHCZ
Symbol/ Ticker:  722 (Frankfurt)
Kürzel:  FRA:722, ETR:722, 722:GR
Index:  -
Webseite:  https://www.antengene.com..
Profil:  Antengene Corporation Limited is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative oncology medicines. The company's primary function is to provide therapeutic solutions for cancer patients, addressin..
>Volltext..
Marktkapitalisierung:  375.48 Mio. EUR
Unternehmenswert:  317.46 Mio. EUR
Umsatz:  12.71 Mio. EUR
EBITDA:  -26.33 Mio. EUR
Nettogewinn:  -28.96 Mio. EUR
Gewinn je Aktie:  -0.04 EUR
Schulden:  31.92 Mio. EUR
Liquide Mittel:  90.97 Mio. EUR
Operativer Cashflow:  -
Bargeldquote:  2.78
Umsatzwachstum:  0.83%
Gewinnwachstum:  33.85%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ANTENGENE
Letzte Datenerhebung:  05.04.26
>ANTENGENE Kennzahlen
Aktien/ Unternehmen:
Aktien: 679.45 Mio. St.
Frei handelbar: 53.08%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 129
Umsatz/Mitarb.: 0.1 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 67.4%
Bewertung:
KGV: -
KGV lG: 9.5
KUV: -
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 64.95%
Gewinnmarge: -227.81%
Operative Marge: -225.78%
Managementeffizenz:
Gesamtkaprendite: -18.38%
Eigenkaprendite: -32.11%
>ANTENGENE Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
20.03.26 - 10:09
 Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability (PR Newswire)
 
SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress. Dr. Jay Mei,......
18.03.26 - 01:33
 Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs (PR Newswire)
 
SHANGHAI and HONG KONG, March 17, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
03.03.26 - 23:03
 Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases (PR Newswire)
 
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune diseases. Antengene will receive USD 80 million of upfront and near-term milestone payments, and is......
25.02.26 - 01:33
 Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) (PR Newswire)
 
SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
25.02.26 - 01:33
 Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) (GlobeNewswire EN)
 
Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)...
16.01.26 - 02:01
 Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs (PR Newswire)
 
SHANGHAI and HONG KONG, Jan. 15, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
17.12.25 - 02:01
 Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma (PR Newswire)
 
SHANGHAI and HONG KONG, Dec. 16, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
02.12.25 - 10:03
 Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy (PR Newswire)
 
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
20.11.25 - 03:57
 Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs (PR Newswire)
 
SHANGHAI and HONG KONG, Nov. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for......
27.10.25 - 02:03
 Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025 (PR Newswire)
 
SHANGHAI and HONG KONG, Oct. 26, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for......
20.10.25 - 10:36
 Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability (PR Newswire)
 
SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 ADC), were presented in a Poster Presentation at ESMO 2025. Details of the......
19.09.25 - 14:03
 Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025 (PR Newswire)
 
SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
25.08.25 - 09:03
 Antengene Announces 2025 Interim Results with Encouraging Clinical Data and Progress in TCE Platform (PR Newswire)
 
SHANGHAI and HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its interim results for the period ending June 30, 2025, along with updates on recent achievements: ATG-022 (CLDN18.2 ADC) has shown promising results in the......
22.08.25 - 12:15
 Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform (PR Newswire)
 
The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression......
19.08.25 - 12:42
 Antengene′s ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma (PR Newswire)
 
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......
28.07.25 - 04:33
 Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025 (PR Newswire)
 
SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines......
23.05.25 - 06:02
 Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 (PR Newswire)
 
ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing......
20.05.25 - 14:03
 Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab) (PR Newswire)
 
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical......
26.04.25 - 02:33
 Antengene Presents Four Posters at AACR 2025 Highlighting Focuses on AnTenGagerTM TCEs and Synthetic Lethality (PR Newswire)
 
SHANGHAI and HONG KONG, April 25, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines......
24.04.25 - 04:21
 Antengene to Present Latest Results From Two Clinical Studies at ASCO 2025 (PR Newswire)
 
SHANGHAI and HONG KONG, April 23, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!